The International Myeloma Foundation (IMF) will host the 9th Annual International Myeloma Working Group (IMWG) Summit from June 11–13 in Stockholm, Sweden. More than 100 of the world’s top myeloma experts will attend the 2018 Summit, which convenes on the eve of the 23rd Annual Congress of the European Hematology Association (EHA), also in Stockholm. Throughout the IMWG Summit, myeloma experts will debate how best to treat patients in 2018 and beyond.

At the Summit, working groups will tackle significant questions surrounding multiple myeloma, an approach that regularly results in the publication of well-respected IMWG treatment guidelines used by physicians and cited by researchers hundreds of times annually. 

The Summit provides the opportunity for us to evaluate the latest developments in myeloma research and treatment, and come to a consensus on how best to incorporate these advances into recommendations for improving treatment for myeloma patients globally.

From CAR T-cell therapy to testing technologies

Topics we will address in Sweden include CAR T-cell therapy and other immune therapy approaches; the best treatment for early relapse; the role of transplant; and innovative new myeloma testing technologies. In addition, investigators from the IMF’s Black Swan Research Initiative® (BSRI) team will meet to determine the next steps in the IMF’s effort to find the pathway to cure myeloma.

Patients, caregivers, and doctors around the world can watch a live-stream broadcast from the Summit on Wednesday, June 13. During the IMF’s popular IMWG Conference Series, "Making Sense of Treatment," Dr. María-Victoria Mateos, IMF Chief Medical Officer Dr. Joseph Mikhael, and myself will distill, debate, and discuss up-to-the minute myeloma news from the Summit, from the European Hematological Association (EHA) meeting, and from the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). This 60-minute live webcast will start at 6 a.m. EST. An archived version will also be available.

Additional highlights from Stockholm include:

  • Presentation of the IMF’s Annual IMWG Awards. Prof. Philippe Moreau, MD, will receive the 16th Annual Robert A. Kyle Lifetime Achievement Award. The award honors an individual whose body of work has made significant contributions to myeloma research and patient care. Dr. Sigurdur Y. Kristinsson will receive the inaugural Brian G.M. Durie Outstanding Achievement Award, which recognizes excellence in myeloma research.

  • The IMF Global Myeloma Action Network (GMAN) Summit. More than 30 myeloma patient groups from around the world will gather to raise global awareness of myeloma, improve patient outcomes, and ensure access to life-saving treatments.

As the IMF President Susie Novis Durie says, “The IMF is proud to lead this unprecedented collaborative event that brings together the world’s experts in myeloma to advance treatment and research that will lead to a cure.”


Dr. Durie sincerely appreciates and reads all comments left here. However, he cannot answer specific medical questions and encourages readers to contact the trained IMF InfoLine staff instead. Specific medical questions posted here will be forwarded to the IMF InfoLine. Questions sent to the InfoLine are answered with input from Dr. Durie and/or other scientific advisors and IMWG members as appropriate, but will not be posted here. To contact the IMF InfoLine, call 800-452-CURE, toll-free in the US and Canada, or send an email to infoline@myeloma.org. InfoLine hours are 9 am to 4 pm PT. Thank you.

Previous Post
If a myeloma patient has MRD-negative status, does that mean that patient is cured?
Next Post
If you have myeloma, should you undergo tests for DNA sequencing?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.